Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Novartis
Fish and Richardson
Teva
Covington
Argus Health
Johnson and Johnson
Federal Trade Commission
Merck
Daiichi Sankyo

Generated: August 24, 2017

DrugPatentWatch Database Preview

Suvorexant - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for suvorexant and what is the scope of suvorexant patent protection?

Suvorexant
is the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Suvorexant has fifty patent family members in thirty-four countries.

One supplier is listed for this compound.

Summary for Generic Name: suvorexant

Tradenames:1
Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list36
Clinical Trials: see list21
Patent Applications: see list35
Drug Prices:see low prices
DailyMed Link:suvorexant at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-003Aug 13, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-004Aug 13, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-004Aug 13, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-001Aug 13, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-002Aug 13, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-003Aug 13, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-002Aug 13, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-001Aug 13, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: suvorexant

Country Document Number Estimated Expiration
Japan2011068665► Subscribe
South Korea20100031767► Subscribe
China101627028► Subscribe
Canada2670892► Subscribe
Taiwan200831494► Subscribe
EcuadorSP099374► Subscribe
Slovenia2089382► Subscribe
Russian Federation2010150818► Subscribe
TaiwanI513696► Subscribe
Denmark2089382► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Colorcon
QuintilesIMS
McKinsey
Accenture
Daiichi Sankyo
Medtronic
Express Scripts
UBS
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot